Cat. No. 2675
Chemical Name: N-[[[(1S)-1-Carboxy-3-methylbutyl]a
Biological ActivityPotent inhibitor of glutamate carboxypeptidase II and III (GCP II and III/NAAG peptidase/NAALADase) (Ki values are 0.8 and 23 nM respectively) that inhibits the hydrolysis of NAAG (IC50 = 2.4 nM) . Does not directly interact with NMDA or metabotropic glutamate receptors. Reduces neuronal degeneration in a rat model of traumatic brain injury (TBI) and reduces locomotor activity in the PCP-model of schizophrenia.
Licensing InformationSold with the permission of Acenta Discovery, Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Yamamoto et al (2007) Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur.J.Neurosci. 25 147. PMID: 17241276.
Zhou et al (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat.Rev.Drug Discov. 4 1015. PMID: 16341066.
Olszewski et al (2004) NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J.Neurochem. 89 876. PMID: 15140187.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses ZJ 43 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: ZJ 43, supplier, Glutamate, carboxypeptidase, II, III, NAALADase, NAAG, peptidase, inhibitors, inhibits, Carboxypeptidase, GCP, Peptidase, Proteinases, Proteases, ZJ43, Tocris Bioscience, Carboxypeptidase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent 20S proteasome inhibitorDiprotin A
Dipeptidyl peptidase IV (DPP-IV) inhibitorAcein
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailable
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands